At a turning point: Healthcare systems in Central and Eastern Europe

As governments rise to the challenge of managing the interlinked dynamics of population health and economic uncertainty, At a turning point: Healthcare systems in Central and Eastern Europe highlights the key differences and commonalities in healthcare financing and policy approaches across 13 European countries. The report, written by the Economist Impact, identifies major trends and aims to benchmark access and provision of healthcare services, medicines, healthcare outcomes as well as quality of care. It also puts forward a number of recommendations for action, in areas such as financing models, delivery of care, access to innovative treatments, diagnostics and digital infrastructure.

News
5 Dec 2022
Healthcare
At a turning point: Healthcare systems in Central and Eastern Europe

As governments rise to the challenge of managing the interlinked dynamics of population health and economic uncertainty, At a turning point: Healthcare systems in Central and Eastern Europe highlights the key differences and commonalities in healthcare financing and policy approaches across 13 European countries. The report, written by the Economist Impact, identifies major trends and aims to benchmark access and provision of healthcare services, medicines, healthcare outcomes as well as quality of care. It also puts forward a number of recommendations for action, in areas such as financing models, delivery of care, access to innovative treatments, diagnostics and digital infrastructure.

A series of country profiles complement the study, featuring detailed data and additional analysis on the national dynamics. Country profiles are available for seven of the CEE countries: Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovakia and Slovenia. Romania has been included in this study as a comparator country. Additionally, you can find here a presentation outlining the background and objectives of the main study, as well as the key findings and recommendations for action.

Related items

News
27 Oct 2025

Advancing EU health policy through competitiveness and innovation

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda. 

Healthcare
Read more
Read more about Advancing EU health policy through competitiveness and innovation
News
9 Oct 2025

Advancing European healthcare in Strasbourg

From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation. 

Healthcare
Read more
Read more about Advancing European healthcare in Strasbourg
How the Critical Medicines Act will strengthen Europe’s life sciences sector
News
4 May 2025

How the Critical Medicines Act will strengthen Europe’s life sciences sector

On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU. 

Healthcare
Read more
Read more about How the Critical Medicines Act will strengthen Europe’s life sciences sector